

was diagnosed by GUSTO protocol (4). Patients were studied with intention to treat and AHA treatment guidelines (5) of AMI were followed. All patients in the cohort received thrombolysis. The mean symptom to needle time was 8 hours. Patients with preexisting cardiac failure and evidence for old MI were the exclusion criteria as assessment of LV function was one of the aim of the study. The Primary end point was in hospital death. All patients were observed for clinical left ventricular failure, ventricular tachycardia and fibrillation and left ventricular systolic function was assessed by echocardiography. Serum phosphate was estimated by kinetic assay method using ERBA 5 plus semiautoanalyser on days 0, 1, 3 and 5. The first sample was taken immediately on arrival. Hypophosphatemia was diagnosed when the 3 of the 4 samples were <2.5 mg/dl. (Normal 2.6–4.5 mg/dl). All patients were subjected to M mode and 2D Echocardiographic study with Vingmed CFM 725 machine between day 3 and 5

after admission. Measurements were obtained according to American Society of Echocardiography Guidelines (6). Ejection fraction (EF) was calculated by modified simpson method. All patients were followed for 30 days.

RESULTS

Hypophosphatemia was observed in 27% of AMI patients (11/40). These patients formed group 1 of the study. The rest 73% patients (29/40) with normal phosphate levels




Fig.1: Relationship between serum phosphate and ejection fraction.

TABLE I: Summary of results.

	Group I	Group II	P value
Total no of patients (40)	11/40	29/40	-
Location of MI			
AWMI	8	20	NS
IWMI	3	9	
Clinical LVF	6/11 (54%)	5/29 (18%)	< .05
VT/VF	4/11 (36%)	3/29 (11%)	< .05
Mean Phosphate Mg/DI	1.95 (Range 1.56–2.82)	3.96 (Range 3.23–5.92)	<.001
Ejection Fraction	.35 (Range .20–.50)	.53 (Range .30–.65)	<.001
In hospital Mortality	28% (3/11)	6.8% (2/29)	<.001

AWMI: Anterior wall myocardial infarction. IWMI: Inferior wall myocardial infarction.
LVF: Left ventricular failure, VT, VF: Ventricular tachycardia, Ventricular fibrillation.

formed group 2. Results are summarised in the Table. In hospital mortality of the group 1 was 28% (3/11) while in group 2 was 6.8% (2/29). Clinical left ventricular failure was observed in 54% (6/11) of patients in group 1 and it was 18% (5/29) in group 2 (P value <.05). Incidence of ventricular arrhythmias in group 1 was 36% (4/11) and in group 2 was 11% (3/29). The two groups were analysed by paired T test for the P value. The mean EF and the in-hospital mortality showed the strongest statistical significance between the two groups (P<.001). The incidence of clinical LVF and ventricular arrhythmias were significantly higher in group 1 (P >.05). There was a non significant association between anterior myocardial infarctions and hypophosphatemia (P value .15)

DISCUSSION

Mechanism of early pump failure in ischemia is speculative because of complex relationship between ATP depletion and reduced myocardial contractility. Besides magnetic resonance spectroscopy has revealed heterogeneous distribution of high energy phosphates (7). One of the hypothesis advanced is the accumulation of inorganic phosphates in ischemic myocardium at the expense of high energy phosphates (8). The phosphates then trap calcium resulting in sequestration of calciumphosphate in regions of myocardium making this cation unavailable for excitation contraction coupling. Studies correlating low phosphate with early pump failure in animal models are available in the literature (9). Similar studies are lacking in humans.

Our aim is to establish correlation if any between serum phosphate levels, LV

function and mortality. There was a linear correlation between hypophosphatemia and LV dysfunction (Fig. 1) and the 30 day mortality was significantly higher in hypophosphatemic patients. It's well known that LV dysfunction and mortality are influenced by the location of myocardial infarction. However, in our study we found low phosphate level to be an independent predictor in LV function and mortality since the study cohort in terms of location of infarction were comparable.

Limitation of this study is that extracellular inorganic phosphate depletion has been taken as surrogate marker of intracellular high energy phosphate depletion. Biochemical basis of this relationship is still not clear and is no linear correlation between them.

Clinical implication

Metabolic modification and supporting of ischemic myocardium is a new development in the management of acute coronary syndrome in recent times. This has been especially important in diabetic subjects. Knowledge of intracellular high energy phosphate stores helps in selecting the particular subset of patients who will benefit by appropriate interventions. One exciting new development is availability of intravenous ATP infusion (10). Further studies will be required to address this issue.

Conclusion

We conclude that hypophosphatemia in AMI is associated with LV dysfunction which results in increased 30 day mortality.

REFERENCES

1. Yaroslavsky A, Blum M, Peer G et al. Serum phosphate shift in acute myocardial infarction. *Am Heart J* 1982; 104: 884-885.
2. Heusch G, Schulz R. Hibernating myocardium a review. *J Mol Cell Cardiol* 1996; 28: 2359-2372.
3. Ognibene A, Cinigilo R, Grefenstain A et al. Ventricular tachycardia in acute myocardial infarction: the role of hypophosphatemia. *South Med J* 1994; 65-69.
4. The GUSTO investigators: An international randomised trial comparing four thrombolytic strategies for acute myocardial infarction. *N Engl Med* 1993 ;329: 673-682.
5. Ryan TJ, Anderson JL, Antman EM et al. ACC/AHA guidelines for the management of patients with acute myocardial infarction. *J Am Cardiol* 1996; 28: 1328-1428.
6. Aoki T, Nishikawa H, Motayasu M et al. A case of stunned myocardium with marked ^{99m}Tc -PYP accumulation. *Kaku Igaku* 1993; 30: 61.
7. Scholz TD, Grover-McKay M, Fleagle SR et al. Quantitation of the extent of acute myocardial infarction by phosphorus-31 nuclear magnetic resonance spectroscopy. *J Am Coll Cardiol* 1991; 18: 1380-1387.
8. Kubler W, Kate AM. Mechanism of early pump failure of the ischemic heart: possible role of adenosine depletion and inorganic phosphphate accumulation. *Am J Cardiol* 1977; 40: 467.
9. Jennings RB, Hawkins HK, Lowe JE et al. Relation between high energy phosphate and lethal in myocardial ischemica in the dog. *Am J Pathol* 1978; 92: 187-214.
10. Komarek J, Stransova V et al. Creatinei phosphate as a drug in acute myocardial infarction. *Cas Lek Cesk* 1992; 24: 131(8): 248.